Latest / Razib Khan's Unsupervised Learning / Halie May: the democratization of genomics
Transcript
- 0:00SPEAKER_00: This podcast is brought to you by the Albany Public Library Main Branch and the
- 0:04SPEAKER_00: generosity of listeners like you.
- 0:09SPEAKER_00: What is a podcast?
- 0:16SPEAKER_00: God, Daddy, these people talk as much as you do.
- 0:26SPEAKER_00: Razeeb Khan's Unsupervised Learning
- 0:29SPEAKER_00: Embryos have a 30% to 60% difference in the predisposition to severe diseases.
- 0:33SPEAKER_00: With ORCID, parents can identify their embryo at lowest genetic risk rather than just a random outcome.
- 0:38SPEAKER_00: Our genetic calculator can show the impact of embryo selection.
- 0:41SPEAKER_00: Discuss embryo screening and IVF with a genetics expert.
- 0:45SPEAKER_00: Hey everybody,
- 0:45SPEAKER_00: this is Razeeb with the Unsupervised Learning Podcast,
- 0:48SPEAKER_00: and today we're going to be talking about genetics,
- 0:51SPEAKER_00: but more in a news-you-can-use-to-quote-the-old-US-news tagline sense than usual.
- 0:58SPEAKER_00: I'm not going to be talking about H-DNA or anything like that.
- 1:01SPEAKER_00: I am here with Hallie May, who is a genetic counselor.
- 1:04SPEAKER_00: Hallie,
- 1:04SPEAKER_00: can you talk about just your background,
- 1:06SPEAKER_00: your education,
- 1:07SPEAKER_00: what you do,
- 1:08SPEAKER_00: where you work,
- 1:08SPEAKER_00: that sort of thing?
- 1:09SPEAKER_01: Sure.
- 1:10SPEAKER_01: I've been practicing.
- 1:11SPEAKER_00: I got to say, you have a sub stack too.
- 1:13SPEAKER_00: So I'll put the link for the sub stack if you're not there.
- 1:15SPEAKER_00: All right.
- 1:16SPEAKER_00: Yeah.
- 1:17SPEAKER_01: Awesome.
- 1:17SPEAKER_01: Thank you.
- 1:18SPEAKER_01: Yeah, sure.
- 1:19SPEAKER_01: I graduated six years ago.
- 1:21SPEAKER_01: I graduated from Sarah Lawrence College Genetic Counseling Program in 2018.
- 1:26SPEAKER_01: From there,
- 1:26SPEAKER_01: I started working at Columbia University as a research genetic counselor,
- 1:30SPEAKER_01: and I played sort of a dual role.
- 1:31SPEAKER_01: I did research for gene discovery.
- 1:34SPEAKER_01: I also was a part of the faculty for the genetic counseling program there.
- 1:40SPEAKER_01: And I did clinic as well.
- 1:41SPEAKER_01: I did some kidney clinic, kidney genetics clinic.
- 1:45SPEAKER_01: After that,
- 1:46SPEAKER_01: I worked at a startup company for a short stint,
- 1:49SPEAKER_01: and then now I work at Natera in their oncology space.
- 1:53SPEAKER_00: Cool.
- 1:53SPEAKER_00: What startup was it, out of curiosity?
- 1:56SPEAKER_01: Called Tomorrow's Health.
- 1:58SPEAKER_00: Okay.
- 1:58SPEAKER_01: Yeah.
- 2:00SPEAKER_00: Okay, cool.
- 2:01SPEAKER_00: So, obviously, genetic counselor, it's a little bit of tautology in terms of what that means to people.
- 2:10SPEAKER_00: People have a general idea.
- 2:12SPEAKER_00: But can you tell, just at the high level, for people out there, and a lot of people...
- 2:18SPEAKER_00: They're going to encounter a genetic counselor today,
- 2:20SPEAKER_00: I think,
- 2:20SPEAKER_00: in the United States,
- 2:22SPEAKER_00: mostly if there's genetic disease in the family,
- 2:25SPEAKER_00: they're about to have kids,
- 2:26SPEAKER_00: I think,
- 2:26SPEAKER_00: right?
- 2:27SPEAKER_00: In the future, it might be different.
- 2:29SPEAKER_00: But that partly depends on how many genetic counselors we have, that sort of stuff.
- 2:33SPEAKER_00: But can you talk about what a genetic counselor does, like when you bring in a genetic counselor?
- 2:37SPEAKER_01: Yeah, I think you're right.
- 2:39SPEAKER_01: I'm usually explaining to people what I do and what a genetic counselor is.
- 2:43SPEAKER_01: And the people that do know what a genetic counselor is are usually people who have
- 2:46SPEAKER_01: been through pregnancies before.
- 2:47SPEAKER_01: So I think that's accurate.
- 2:49SPEAKER_01: So genetic counselors broadly are clinical providers that work with the rest of the health care team.
- 2:55SPEAKER_01: to support patients through the genetic testing process.
- 2:59SPEAKER_01: So that means everything from seeing a patient for an initial consult and taking a
- 3:03SPEAKER_01: very thorough family history,
- 3:05SPEAKER_01: seeing what conditions they may be at risk for,
- 3:08SPEAKER_01: either based on their family history or based on any of their symptoms that they've
- 3:12SPEAKER_01: had or any conditions that they've had in their lifetime.
- 3:14SPEAKER_01: They will facilitate genetic testing,
- 3:17SPEAKER_01: starting by speaking about the genetic testing options that are available to them,
- 3:23SPEAKER_01: helping them and make
- 3:24SPEAKER_01: informed decisions to make sure that they know what testing they're ordering,
- 3:28SPEAKER_01: discussing the benefits and limitations of testing.
- 3:31SPEAKER_01: Once the testing is complete,
- 3:32SPEAKER_01: they'll be able to talk to the patient about the interpretation,
- 3:37SPEAKER_01: whether that's a negative result,
- 3:38SPEAKER_01: a positive result,
- 3:39SPEAKER_01: or whether there's a variant of uncertain significance there,
- 3:41SPEAKER_01: and loop in any other providers needed.
- 3:43SPEAKER_01: They also can give a lot of great resources for patients.
- 3:47SPEAKER_01: And then, of course, in non-clinical spaces, genetic counselors work everywhere from
- 3:52SPEAKER_01: industry to research to start up a lot of the places that I described that I've worked myself.
- 3:57SPEAKER_00: Yeah.
- 3:57SPEAKER_00: So I, I know what Natera does.
- 4:00SPEAKER_00: I know people that work at Natera,
- 4:01SPEAKER_00: but can you talk to,
- 4:02SPEAKER_00: can you tell the,
- 4:03SPEAKER_00: tell the listener what Natera does?
- 4:04SPEAKER_00: Cause it's a big name in, in genetics, but outside of genetics, it's not.
- 4:08SPEAKER_00: So, you know,
- 4:10SPEAKER_01: Sure.
- 4:10SPEAKER_01: Yeah.
- 4:10SPEAKER_01: Natera is a genetic testing company.
- 4:13SPEAKER_01: They really started in the women's health space.
- 4:15SPEAKER_01: And so again, when I say genetic, people know genetic counselors from working through pregnancies.
- 4:21SPEAKER_01: They may be familiar with Natera's cell-free DNA test, which is commonly ordered during pregnancies.
- 4:28SPEAKER_01: Natera has now branched out into the oncology space.
- 4:30SPEAKER_01: And so I support their inherited cancer tests.
- 4:33SPEAKER_01: They also use cell-free DNA technology for a tumor detection test.
- 4:39SPEAKER_00: Yeah, so you said a variant of uncertain significance.
- 4:45SPEAKER_00: People,
- 4:45SPEAKER_00: when they think of genetics,
- 4:47SPEAKER_00: they often think of,
- 4:49SPEAKER_00: okay,
- 4:49SPEAKER_00: you get a test and it's like yay or nay,
- 4:51SPEAKER_00: and a baby should be able to read this test,
- 4:54SPEAKER_00: right?
- 4:55SPEAKER_00: That's really not
- 4:57SPEAKER_00: First of all,
- 4:58SPEAKER_00: when it is like that,
- 4:59SPEAKER_00: it often goes through some sort of analytical pipeline and stuff like that.
- 5:03SPEAKER_00: But even the end result of a test with things like base rate errors and all these
- 5:09SPEAKER_00: other issues,
- 5:10SPEAKER_00: it requires interpretation.
- 5:11SPEAKER_00: Can you talk about the interpretive,
- 5:13SPEAKER_00: what you as a genetic counselor,
- 5:15SPEAKER_00: what genetic counselors often bring to the table,
- 5:17SPEAKER_00: that sort of thing?
- 5:19SPEAKER_01: Yeah, so...
- 5:20SPEAKER_01: Unfortunately,
- 5:21SPEAKER_01: there are many times variants of uncertain significance,
- 5:23SPEAKER_01: which means that there is a base pair of your DNA that's different than what we see
- 5:30SPEAKER_01: typically in the majority of the population,
- 5:32SPEAKER_01: but we're not sure if it's actually causing a condition.
- 5:35SPEAKER_01: We're not sure if it's harmful or not.
- 5:37SPEAKER_01: And usually it's because there's not enough information for that.
- 5:41SPEAKER_01: So it hasn't been seen in enough people to be able to identify whether it's harmful.
- 5:45SPEAKER_01: And so when you're trying to decide whether a mutation is harmful or not,
- 5:49SPEAKER_01: or I should say variants really,
- 5:50SPEAKER_01: it
- 5:50SPEAKER_01: mutation is an outdated term,
- 5:53SPEAKER_01: you're going to be looking at specifically the type of variant it is in the gene
- 5:56SPEAKER_01: because there are some genes,
- 5:58SPEAKER_01: for example,
- 5:59SPEAKER_01: where loss of function variants,
- 6:01SPEAKER_01: where it's something where the loss of protein function is going to be detrimental
- 6:07SPEAKER_01: to the gene and then impair its function.
- 6:10SPEAKER_01: There's other genes where it's actually gain of function variants that are going to
- 6:14SPEAKER_01: be detrimental to the gene.
- 6:15SPEAKER_01: So you want to see what type of mutation it is.
- 6:18SPEAKER_01: You want to see where it is in
- 6:20SPEAKER_01: the population frequency.
- 6:23SPEAKER_01: There's major population databases, public databases for that.
- 6:27SPEAKER_01: There's also internal databases in each lab.
- 6:29SPEAKER_01: So they might use a combination of both.
- 6:32SPEAKER_01: And then there's going to be the literature review and analysis to understand where
- 6:37SPEAKER_01: this variant may have been seen before.
- 6:40SPEAKER_01: There's also some analytical algorithms that can predict whether this is going to impact protein or not.
- 6:47SPEAKER_00: Yeah,
- 6:47SPEAKER_00: I will say that the field we're in,
- 6:52SPEAKER_00: genetics,
- 6:54SPEAKER_00: it's not like,
- 6:55SPEAKER_00: I don't know,
- 6:55SPEAKER_00: let me do something else.
- 6:56SPEAKER_00: It's not like Newtonian mechanics.
- 6:58SPEAKER_00: It's not like a science where you have a book, you have a reference book, and
- 7:03SPEAKER_00: You pretty much understand it.
- 7:05SPEAKER_00: Maybe there's a few things on the margin.
- 7:07SPEAKER_00: The last 20 years have been really crazy.
- 7:10SPEAKER_00: And every time you talk to a geneticist, there's going to be new discoveries.
- 7:14SPEAKER_00: That doesn't mean that everything is obviously overruled,
- 7:17SPEAKER_00: but a variant that might be of unknown significance in 2018 may have changed by 2021.
- 7:26SPEAKER_00: And so you've always got to be checking these databases.
- 7:29SPEAKER_00: That's part of the learning in the field.
- 7:33SPEAKER_01: Yeah.
- 7:34SPEAKER_01: And what's interesting is there's not even a whole lot of consensus in that among clinical labs.
- 7:39SPEAKER_01: There are some labs that will take that responsibility and will say that we will
- 7:43SPEAKER_01: notify patients if we reclassify a variant.
- 7:46SPEAKER_01: Natera does that.
- 7:47SPEAKER_01: Not all labs do that.
- 7:48SPEAKER_01: And a lot of times it is on the responsibility of the patient to be checking back
- 7:52SPEAKER_01: with their provider,
- 7:53SPEAKER_01: with their genetic counselor to see if there's been any updates.
- 7:55SPEAKER_01: So it's really dependent and there's not a standard in the field, but it changes very quickly.
- 8:00SPEAKER_01: Yeah.
- 8:00SPEAKER_01: Because studies are published all the time.
- 8:03SPEAKER_00: Yeah,
- 8:03SPEAKER_00: I mean,
- 8:04SPEAKER_00: just really,
- 8:05SPEAKER_00: yeah,
- 8:05SPEAKER_00: really quickly,
- 8:06SPEAKER_00: I guess we should,
- 8:07SPEAKER_00: like,
- 8:08SPEAKER_00: I want to just define a few things first so that,
- 8:11SPEAKER_00: you know,
- 8:11SPEAKER_00: I think a lot of the listeners will kind of know what we're talking about in terms
- 8:13SPEAKER_00: of variants,
- 8:14SPEAKER_00: but just so you guys know,
- 8:15SPEAKER_00: obviously,
- 8:15SPEAKER_00: you know,
- 8:16SPEAKER_00: there's a reference human genome,
- 8:17SPEAKER_00: and the reference human genome has 3 billion base pairs,
- 8:20SPEAKER_00: most of which are not variable.
- 8:22SPEAKER_00: Small minority are variable.
- 8:24SPEAKER_00: You know, hundreds of millions, there's 100 million or so variants out there.
- 8:28SPEAKER_00: So Holly used the word variant because variants,
- 8:31SPEAKER_00: you don't know what that variant could be.
- 8:32SPEAKER_00: It could be a single nucleotide polymorphism,
- 8:34SPEAKER_00: most of them,
- 8:35SPEAKER_00: or it could be a deletion,
- 8:37SPEAKER_00: or it could be some copy number variant,
- 8:39SPEAKER_00: some sort of structural variant.
- 8:40SPEAKER_00: And so you use variant as kind of a catch-all term.
- 8:44SPEAKER_00: And I'm assuming that she's trying to avoid the word mutation,
- 8:46SPEAKER_00: or that's a word you kind of don't want to use because it makes it seem like
- 8:50SPEAKER_00: The mutation is the weird one, and there's the wild type.
- 8:53SPEAKER_00: Actually, that's not always true.
- 8:55SPEAKER_00: So actually, as of this recording, I just put up a post about lactose tolerance, lactase persistence.
- 9:03SPEAKER_00: And this is actually a classic case where initially it was considered a disease or –
- 9:10SPEAKER_00: It was kind of considered a disease to be lactose intolerant.
- 9:12SPEAKER_00: That turns out to be the wild type.
- 9:14SPEAKER_00: That turns out to be the ancestral state.
- 9:17SPEAKER_00: And 70% of the people in the world are lactose intolerant.
- 9:21SPEAKER_00: And so they have to like flip it all back around.
- 9:23SPEAKER_00: So the mutation is lactose tolerance.
- 9:26SPEAKER_00: Now, that's not a disease either, right?
- 9:28SPEAKER_00: And so that's why when you,
- 9:30SPEAKER_00: you know,
- 9:30SPEAKER_00: if you say,
- 9:31SPEAKER_00: you know,
- 9:32SPEAKER_00: for the general public,
- 9:33SPEAKER_00: well,
- 9:34SPEAKER_00: I mean,
- 9:34SPEAKER_00: you know,
- 9:35SPEAKER_00: in genetics,
- 9:35SPEAKER_00: you would just say ancestral drive.
- 9:36SPEAKER_00: That's the easiest way to say it.
- 9:38SPEAKER_00: But like, what does that mean?
- 9:39SPEAKER_00: So with general public, you still use mutation, but it has certain connotations.
- 9:41SPEAKER_00: When you say something is a mutation...
- 9:44SPEAKER_00: It's not a great thing, but the reality is it could just have a different function.
- 9:48SPEAKER_00: It could have no different function.
- 9:51SPEAKER_00: It's like a silent mutation of some sort.
- 9:53SPEAKER_00: And then you're talking about loss of function.
- 9:55SPEAKER_00: Those are really straightforward, supposedly.
- 9:57SPEAKER_00: It's like, okay, the protein...
- 9:59SPEAKER_00: The protein is like borked somehow, okay?
- 10:01SPEAKER_00: Maybe it doesn't even produce a protein.
- 10:02SPEAKER_00: Maybe it's a stop.
- 10:03SPEAKER_00: But there are cases with loss of function.
- 10:06SPEAKER_00: And Dan MacArthur's lab, he was at Mass General and now he's in Sydney, I think.
- 10:11SPEAKER_00: They've studied people that have loss of functions that should, I think, be lethal, but they're fine.
- 10:18SPEAKER_00: So why is that?
- 10:20SPEAKER_00: These are the sort of uncertainties that you're grappling with and have to communicate to people, right?
- 10:23SPEAKER_01: Right.
- 10:24SPEAKER_01: And that's why a lot of times you can't really,
- 10:27SPEAKER_01: there are some types of variants where you can't even properly classify it without
- 10:31SPEAKER_01: a functional study or an animal model.
- 10:32SPEAKER_01: Especially,
- 10:33SPEAKER_01: for example,
- 10:34SPEAKER_01: if it's in the splice site region of a gene,
- 10:37SPEAKER_01: that is something where you can't actually see if it's going to impact function
- 10:40SPEAKER_01: unless you do a mouse model or something like that or a cell model.
- 10:43SPEAKER_01: So you're exactly correct.
- 10:45SPEAKER_01: A lot of times you just don't know.
- 10:46SPEAKER_00: Do you want to explain the splice?
- 10:48SPEAKER_00: Do you want to explain why splicing is a big deal?
- 10:52SPEAKER_00: A lot of listeners are not going to know what that means because that is a big deal.
- 10:55SPEAKER_00: So really quickly, a splice site, so you have a genome.
- 10:58SPEAKER_00: When you have a bacteria, you just read it.
- 11:00SPEAKER_00: It just reads from DNA to RNA to protein, right?
- 11:03SPEAKER_00: But in complex organisms like us,
- 11:06SPEAKER_00: and I'm assuming all the listeners are metazoans,
- 11:09SPEAKER_00: you have splicing,
- 11:11SPEAKER_00: which means that you take
- 11:12SPEAKER_00: uh,
- 11:13SPEAKER_00: the transcribed,
- 11:14SPEAKER_00: you know,
- 11:14SPEAKER_00: parts that translate into protein and you can recombine them in different ways.
- 11:19SPEAKER_00: Right.
- 11:19SPEAKER_00: And so that's why you get way more,
- 11:22SPEAKER_00: you know,
- 11:22SPEAKER_00: I mean,
- 11:22SPEAKER_00: the theory is,
- 11:23SPEAKER_00: or the way they explain it,
- 11:23SPEAKER_00: that's how you get so much more variation and you're so much more complex,
- 11:27SPEAKER_00: but your genome is like,
- 11:28SPEAKER_00: you know,
- 11:28SPEAKER_00: a 30th the size of a lungfish.
- 11:30SPEAKER_00: Uh, it's just not my mind.
- 11:31SPEAKER_00: Cause I was the lungfish genome just came out.
- 11:33SPEAKER_00: It's 30 times bigger because of transprosons, whatever.
- 11:36SPEAKER_00: It's all crap, but who cares?
- 11:37SPEAKER_00: You know, it's like impressive to people, you know?
- 11:40SPEAKER_01: Yeah,
- 11:41SPEAKER_01: the splice site is that boundary between the intron,
- 11:45SPEAKER_01: the non-protein coding DNA,
- 11:46SPEAKER_01: and the coding DNA.
- 11:47SPEAKER_01: And so there's just slippery spots there.
- 11:51SPEAKER_00: You know, we've been kind of getting a little bit into the weeds already, obviously.
- 11:55SPEAKER_00: But I want to take a step back.
- 11:57SPEAKER_00: You've been in the field, you've been in a changing field for a while now.
- 12:02SPEAKER_00: I mean...
- 12:04SPEAKER_00: In terms of the length of the field,
- 12:06SPEAKER_00: it's actually not a trivial amount,
- 12:08SPEAKER_00: even if you think your career is new.
- 12:10SPEAKER_00: You know what I'm saying?
- 12:11SPEAKER_00: Can you talk about – have you noticed any changes just recently in terms of accessibility of genetics?
- 12:18SPEAKER_00: I mean you have companies like Natera.
- 12:19SPEAKER_00: I mean obviously you work through insurance and stuff like that,
- 12:22SPEAKER_00: but these private sector testing companies like Natera,
- 12:25SPEAKER_00: like Consul,
- 12:27SPEAKER_00: they're democratizing access to a lot of this genetic stuff,
- 12:29SPEAKER_00: right?
- 12:30SPEAKER_00: Yeah.
- 12:30SPEAKER_01: Yeah.
- 12:31SPEAKER_01: Yeah, absolutely.
- 12:32SPEAKER_01: I think that there is increased access to genetic testing services for a lot of reasons.
- 12:38SPEAKER_01: I think that more providers are comfortable ordering genetic testing,
- 12:42SPEAKER_01: are aware of how it impacts their field,
- 12:44SPEAKER_01: and that will be different for different providers.
- 12:47SPEAKER_01: Take oncologists, for example, and I guess that Natera is
- 12:51SPEAKER_01: company that makes sense here to plug as someone who has changed a lot over years
- 12:55SPEAKER_01: and changed with the times and the technology.
- 12:57SPEAKER_01: An oncologist is going to be very familiar with ordering genetic testing because
- 13:03SPEAKER_01: variants in genes that cause different types of cancer or increase risk for
- 13:07SPEAKER_01: different types of cancer can have management impacts.
- 13:10SPEAKER_01: I mean,
- 13:10SPEAKER_01: there are different types of therapies,
- 13:12SPEAKER_01: for example,
- 13:12SPEAKER_01: that are going to work better if you have a specific variant in an inherited gene.
- 13:18SPEAKER_01: So
- 13:19SPEAKER_01: I think that that's becoming more common practice.
- 13:21SPEAKER_01: And so you'll get oncologists that are comfortable ordering inherited genetic
- 13:25SPEAKER_01: testing and that are comfortable finding and knowing where to refer those patients to,
- 13:31SPEAKER_01: to where the genetic counselors are.
- 13:32SPEAKER_01: I think, obviously, there's the rise of 23andMe and some of the direct-to-consumer tests.
- 13:38SPEAKER_01: Those were still...
- 13:39SPEAKER_01: out when I was in school, but more so even than when I graduated.
- 13:42SPEAKER_01: And then there's the guidelines that have just been expanded and are more standard
- 13:48SPEAKER_01: of care for more people.
- 13:49SPEAKER_01: So prenatal guidelines,
- 13:51SPEAKER_01: for example,
- 13:52SPEAKER_01: you know,
- 13:52SPEAKER_01: and I called my friend just today who is a prenatal genetic counselor to check
- 13:57SPEAKER_01: myself on this.
- 13:58SPEAKER_01: When I was in school,
- 13:59SPEAKER_01: NIPT,
- 14:01SPEAKER_01: non-invasive prenatal testing,
- 14:02SPEAKER_01: which is cell-free DNA,
- 14:03SPEAKER_01: which is that test that I mentioned before,
- 14:05SPEAKER_01: that's where Natera started.
- 14:07SPEAKER_01: in women's health.
- 14:08SPEAKER_01: This is something that was only recommended for women over the age of 35 when I was in school.
- 14:13SPEAKER_01: And even since then, six years ago, it's now recommended for all women, all ages,
- 14:17SPEAKER_01: no matter where they are, um, as soon as possible in pregnancy.
- 14:20SPEAKER_01: So that's a huge shift.
- 14:21SPEAKER_01: And so you have OBs,
- 14:23SPEAKER_01: GYNs all over the country ordering that because it's actually recommended by ACOG,
- 14:27SPEAKER_01: um,
- 14:27SPEAKER_01: American College of.
- 14:28SPEAKER_00: Okay.
- 14:28SPEAKER_00: Okay.
- 14:29SPEAKER_00: So yeah,
- 14:30SPEAKER_00: this is like a little bit,
- 14:31SPEAKER_00: like I haven't kept track,
- 14:32SPEAKER_00: like,
- 14:32SPEAKER_00: you know,
- 14:32SPEAKER_00: uh,
- 14:33SPEAKER_00: last time that I interacted with the OBGYN industrial complex was the mid teens.
- 14:38SPEAKER_00: Uh, so back then it was, uh, they had just started coming out with NI, NITP, these non-invasive tests.
- 14:44SPEAKER_00: And, uh,
- 14:45SPEAKER_00: It was recommended for 35 and older.
- 14:47SPEAKER_00: Are you saying that's recommended for everybody now?
- 14:50SPEAKER_01: Yeah.
- 14:50SPEAKER_01: So this is how it's stated, is that screening is recommended for everybody.
- 14:55SPEAKER_01: That can be first trimester screening or quad screening,
- 14:59SPEAKER_01: which were the old types of screening before NIPT came out for NIPT.